Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | SCD | O00767 | 5/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13082000 | 0.89 | NPC1 (0.64) | CHRM4SCDPPARAALDH1A1MAPT | |
| SCHEMBL3575995 | 0.87 | CHRM4 (0.61) | CHRM4SCDPPARAALDH1A1MAPT | |
| SCHEMBL244826 | 0.86 | SCD (0.64) | CHRM4SCDALDH1A1NPC1RAB9A | |
| SCHEMBL244641 | 0.85 | SCD (0.58) | CHRM4SCDPPARAMAPTTP53 | |
| SCHEMBL13082592 | 0.85 | MMP13 (0.56) | CHRM4SCDALDH1A1NPC1RAB9A | |
| SCHEMBL13082534 | 0.85 | CHRM4 (0.62) | CHRM4SCDALDH1A1NPC1RAB9A | |
| SCHEMBL3454547 | 0.84 | SCD (0.57) | CHRM4SCDPPARAMAPTTP53 | |
| SCHEMBL13081712 | 0.84 | CYP2C9 (0.64) | CHRM4SCDPPARAALDH1A1NPC1 | |
| SCHEMBL13083004 | 0.83 | MAOB (0.52) | CHRM4SCDALDH1A1NPC1RAB9A | |
| SCHEMBL13083003 | 0.81 | P2RX7 (0.49) | CHRM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236835-B2 | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100029718-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029718-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CHRM4 3011/4885SCD 1/4885PPARA 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.